BEIJING, Aug. 5 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines in China, announced today that it will release its financial results for the second quarter ended June 30, 2010 before the open of the market on Monday, August 16, 2010. The Company will host a conference call on Monday, August 16, 2010 at 8:00 a.m. ET to review the Company's financial results and provide an update on recent corporate developments.
To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call will be available from 11 a.m. ET on August 16, 2010 to August 30, 2010 at midnight. To access the replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (international) and the replay pin number 354766.
A live audio webcast of the call will also be available from the Investors section on the corporate web site at http://www.sinovac.com . A webcast replay can be accessed on the corporate website beginning August 16, 2010 and the replay will remain available for 30 days.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines. Its 30%-owned joint venture, Sinovac Dalian, focuses on the research, development, manufacturing and commercialization of vaccines, such as rabies, chickenpox, mumps and rubella vaccines for human use.
For more information, please contact: Chris Lee Sinovac Biotech Ltd. Tel: +86-10-8279-9659 Fax: +86-10-6296-6910 Email: email@example.com Investors: Amy Glynn/Stephanie Carrington The Ruth Group Tel: +1-646-536-7023/7017 Email: firstname.lastname@example.org email@example.com Media: Jason Rando The Ruth Group Tel: +1-646-536-7025 Email: firstname.lastname@example.org
|SOURCE Sinovac Biotech Ltd.|
Copyright©2010 PR Newswire.
All rights reserved